BC-DXI-843
BC-DXI-843 is a potent and specific AIMP2-DX2 inhibitor with an IC50 of 0.92 μM, more than 100-fold selectivity over AIMP2 (IC50 >100 μM) in a luciferase assay. BC-DXI-843 acts as a promising lead targeting AIMP2-DX2 in lung cancer[1].
Product Specifications
CAS Number
2421117-98-6
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
Aminoacyl-tRNA Synthetase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bc-dxi-843.html
Concentration
10mM
Purity
99.76
Solubility
DMSO : 250 mg/mL (ultrasonic)
Smiles
COC(C=C1)=CC=C1C2=CSC(NC([C@@H](NS(C3=CC=C(C)C=C3)(=O)=O)CC4=CNC5=C4C=CC=C5)=O)=N2
Molecular Formula
C28H26N4O4S2
Molecular Weight
546.66
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
B7-H4 (Immuno-Inhibitory Protein) (B7H4/2652R), CF488A conjugate, 0.1mg/mL
ODC-1 (Ornithine Decarboxylase-1) (ODC1/485), CF405M conjugate, 0.1mg/mL
